The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKGP.L Regulatory News (KGP)

  • There is currently no data for KGP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

13 Nov 2017 07:00

RNS Number : 2382W
Kingspan Group PLC
13 November 2017
 

Kingspan Group Plc

Trading Update

 

13 November 2017

 

Kingspan Group plc, the global leader in high performance insulation and building envelope solutions, today issues a Trading Update, with trading information for the period to 30 September 2017.

Sales in the nine month period to 30 September were €2.69bn, up 19% on the same period in the prior year (+21% pre currency). Sales in the third quarter were up 17% (+20% pre currency). Underlying sales, pre currency and acquisitions, were up 11% in the year to date and were up 13% in the third quarter.

Insulated Panel sales in the first nine months increased by 16% (+18% pre currency), and increased by 13% (+15% pre currency) in the third quarter. Underlying sales were 12% ahead both year to date and in the third quarter, owing significantly to the pass-through of input related inflation. Mainland European sales were solid in most markets and notably positive in France. In the UK we have experienced a sense of near-term indecision around order placement, however our future activity tracker remains modestly ahead of prior year. North America sales were solid overall, and in Latin America we have experienced very encouraging activity since taking a position there in recent months.

Insulation Board sales in the first nine months were up 10% (+13% pre currency) and were up by 16% in quarter three (+19% pre currency). Underlying sales growth was 13% year to date and 19% in the third quarter. Sales growth year on year reflected strong price growth necessitated by raw material inflation. In addition Kooltherm® volume continued to outgrow our other insulation materials, and was particularly positive in the UK, Ireland, Western Europe and the Nordics. The North America and Australasia markets are still in a developmental phase for Kingspan as we are still in the early days of generating demand for high performance insulation in these markets.

 

Light & Air sales both year to date and in the third quarter are strongly ahead reflecting year on year acquisition activity. Underlying sales year to date grew by 4% and by 7% in the third quarter. As we exit 2017 the annualised sales of this division will be in the region of €220m.

Environmental sales in the first nine months were up 12% (+17% pre currency) and were up 11% (+14% pre currency) in the third quarter. A particular highlight was the ongoing growth in rainwater harvesting in Australia. UK and Europe sales were solid overall, and margins continue to progress upwards.

Access Floors sales in the first nine months increased by 2% (+5% pre currency) and were up 4% (+9% pre currency) in the third quarter. UK office activity is softening, as expected, with the US office market remaining relatively flat. Datacentre activity across the division was encouraging as was the continued growth in sales of our broader product portfolio into that segment.

 

Net debt at the end of September 2016 was €479.8m. Net debt at year end is forecast to be in the region of €400m.

 

On the back of significant input inflation in the third quarter, and our associated price inflation, we anticipate this trend to remain through the fourth quarter albeit less pronounced as chemical cost increases reach their peak. In general our end markets are relatively stable, notwithstanding some recent evidence of a slowdown in UK commercial and industrial activity. Separately, the Group's development pipeline is encouraging.

 

Assuming current exchange rates prevail and conscious that much of the seasonally variable fourth quarter remains, we expect to deliver full year trading profit growth of approximately 10% or c. €375m.

 

For further information contact:

 

Gene Murtagh, Chief Executive Officer Tel: +353 (0) 42 9698000

 

Geoff Doherty, Chief Financial Officer Tel: +353 (0) 42 9698000

 

Douglas Keatinge, Murray Consultants Tel: +353 (0) 1 4980300

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTOKKDBOBDDADD
Date   Source Headline
6th Jan 20215:12 pmRNSHolding(s) in Company
5th Jan 20214:03 pmRNSHolding(s) in Company
4th Jan 202110:00 amRNSBlock listing Interim Review
4th Jan 20219:00 amRNSTotal Voting Rights
17th Dec 20209:00 amRNSDirectorate Change
1st Dec 20204:12 pmRNSTotal Voting Rights
16th Nov 20207:00 amRNSTrading Statement
2nd Nov 20201:04 pmRNSDirector/PDMR Shareholding
2nd Nov 202012:19 pmRNSTotal Voting Rights
15th Oct 20205:04 pmRNSDirector/PDMR Shareholding
14th Oct 20201:05 pmRNSDirector/PDMR Shareholding
1st Oct 202012:42 pmRNSTotal Voting Rights
29th Sep 20202:32 pmRNSDirector/PDMR Shareholding
15th Sep 20207:00 amRNSGreen Private Placement
1st Sep 20203:44 pmRNSTotal Voting Rights
24th Aug 20205:34 pmRNSDirector/PDMR Shareholding
24th Aug 20205:27 pmRNSDirector/PDMR Shareholding
21st Aug 20207:00 amRNSHalf-year Report
1st Jul 20206:17 pmRNSBlock listing Interim Review
1st Jul 202011:27 amRNSTotal Voting Rights
25th Jun 20203:44 pmRNSHolding(s) in Company
17th Jun 20204:51 pmRNSHolding(s) in Company
2nd Jun 20203:00 pmRNSTotal Voting Rights
1st May 20203:20 pmRNSResult of AGM
1st May 20209:45 amRNSTotal Voting Rights
30th Apr 20207:00 amRNSTrading Statement
17th Apr 20204:11 pmRNSHolding(s) in Company
17th Apr 20207:00 amRNSStatement re AGM
14th Apr 202011:41 amRNSHolding(s) in Company
1st Apr 202012:46 pmRNSTotal Voting Rights
30th Mar 202011:37 amRNSHolding(s) in Company
23rd Mar 202011:05 amRNSHolding(s) in Company
19th Mar 202012:00 pmRNSDividend Declaration
18th Mar 20209:15 amRNSHolding(s) in Company
2nd Mar 20202:23 pmRNSTotal Voting Rights
28th Feb 202010:38 amRNSAnnual Financial Report
26th Feb 20204:54 pmRNSDirector/PDMR Shareholding
24th Feb 20205:49 pmRNSHolding(s) in Company
24th Feb 20202:26 pmRNSDirector/PDMR Shareholding
24th Feb 202010:10 amRNSDirector/PDMR Shareholding
21st Feb 20207:00 amRNSFinal Results
20th Jan 20209:50 amRNSHolding(s) in Company
3rd Jan 20205:21 pmRNSHolding(s) in Company
2nd Jan 202011:00 amRNSBlock listing Interim Review
2nd Jan 202010:00 amRNSTotal Voting Rights
17th Dec 201910:45 amRNSDirector/PDMR Shareholding
11th Dec 20195:40 pmRNSDirector/PDMR Shareholding
2nd Dec 20192:58 pmRNSTotal Voting Rights
18th Nov 20197:00 amRNSTrading Update
5th Nov 201912:43 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.